🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› California
Clinical trial register · United States · industry-sponsored

Clinical Trials in California, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9115 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 24 Sep 2026, 03:16 UTC
9115
Studies in scope
industry-sponsored, all four open statuses
4955
Recruiting now
open to new participants
2206
Lead sponsors
across recruiting studies
Top states
California 5299 Florida 4396 Illinois 2477 Georgia 2346 Arizona 2230
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca230 Eli Lilly and Company150 AbbVie142 Merck Sharp & Dohme LLC129 Novartis Pharmaceuticals113
State
California5299 Florida4396 Illinois2477 Georgia2346 Arizona2230
All 51 states
Target enrolment
to

Trials with a site in California

5299 of 9115 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Active, closed
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian Participants
NCT06895343Healthy Volunteer
AbbVie
Phase 1
100
California, Illinois
2025-04-03
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 1/2
280
California, Florida, Massachusetts, Missouri, New York, Tennessee, Texas, Washington
2025-04-03
Recruiting
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
NCT06615050Graft-versus-host Disease (GVHD)
Incyte Corporation
Phase 3
572
California, Florida, Georgia, Indiana, Kansas, Massachusetts, Michigan, Missouri
2025-04-02
Active, closed
Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea
NCT06776432Sleep Apnea
Shionogi
Phase 2
60
California, Florida, Massachusetts, Michigan, Minnesota, Ohio, South Carolina, Texas
2025-04-02
Recruiting
A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery
NCT06664775Hemorrhage
Corza Medical GmbH
Phase 3
116
California, Colorado, District of Columbia, Illinois, Indiana, Kentucky, Missouri, North Carolina
2025-04-02
Active, closed
Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011
NCT06925919Rift Valley Fever
IDBiologics, Inc.
Phase 1
40
California
2025-04-02
Active, closed
TECTONIC CAD IVL IDE Study
NCT06885177Coronary Artery Calcification, Coronary Artery Disease, Stenotic Coronary Lesion
Abbott Medical Devices
Not applicable
335
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kansas
2025-04-01
Recruiting
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
NCT06873945Alopecia Areata
Pfizer
Phase 3
674
Alabama, Arkansas, California, Connecticut, Florida, Illinois, Indiana, Iowa
2025-04-01
Recruiting
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
NCT06657144Metastatic Solid Tumor, Advanced Solid Tumor
Coherus Oncology, Inc.
Phase 1
154
Arizona, California, Colorado, Georgia, Louisiana, Michigan, Nevada, New Mexico
2025-04-01
Active, closed
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
NCT06863961Atopic Dermatitis
Hoffmann-La Roche
Phase 2
162
California, Florida, Georgia, Indiana, Michigan, Minnesota, New Jersey, New York
2025-04-01
Recruiting
Behavioral Treatment of Insomnia in Active-Duty Service Members With Traumatic Brain Injury
NCT06867666Insomnia, TBI (Traumatic Brain Injury)
Noctem, LLC
Not applicable
168
California
2025-04-01
Not yet open
Understanding Participation Habits Among Plaque Psoriasis Patients
NCT06338358Plaque Psoriasis
Power Life Sciences Inc.
Observational
500
California
2025-04
By invitation
Research and Engagement on Substance Use: Harnessing Awareness and Personalized Education (RESHAPE) to Improve Well-being and Self-efficacy
NCT06952491Substance Use Disorder (SUD)
Evidation Health
Observational
410
California
2025-04
Not yet open
Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for Major Depressive Disorder (MDD)
NCT06470035Major Depressive Disorder \(MDD, Depressive Disorder, Major
Neurovalens Ltd.
Not applicable
170
California
2025-04
Not yet open
Examining Engagement Trends Among Participants in Peripheral Neuropathy Clinical Research
NCT06338384Peripheral Neuropathy
Power Life Sciences Inc.
Observational
500
California
2025-04
Active, closed
A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease
NCT06807463Celiac Disease
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
50
California, Colorado, Florida, Georgia, Louisiana, Michigan, Minnesota, New York
2025-03-31
Recruiting
Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:
NCT07219927Parkinson Disease
Supernus Pharmaceuticals, Inc.
Observational
120
California, Florida, New York
2025-03-31
Recruiting
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06911112Major Depressive Disorder
Neurocrine Biosciences
Phase 3
200
Alabama, Arkansas, California, Florida, Georgia, Massachusetts, Missouri, New York
2025-03-31
Recruiting
A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
NCT06592638Small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1
30
California, Florida, Kentucky, Ohio, Texas
2025-03-31
Recruiting
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT06917079Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
665
California, Connecticut, Florida, Illinois, Massachusetts, New York, Tennessee, Texas
2025-03-31
Recruiting
A Study of PHST001 in Advanced Solid Tumors
NCT06840886Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma
Pheast Therapeutics
Phase 1
272
California, Colorado, Connecticut, Illinois, Massachusetts, Michigan, New York, North Carolina
2025-03-31
Recruiting
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
NCT06898450Advanced Solid Tumors Cancer, MSI-H Cancer
Nimbus Wadjet, Inc.
Phase 1/2
134
California, Illinois, Kentucky, New York, North Carolina, Ohio, Rhode Island, South Carolina
2025-03-31
Recruiting
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
NCT06750289Eosinophilic Asthma
AstraZeneca
Phase 3
400
Arizona, California, Colorado, Florida, Michigan, Nevada, New Jersey, New York
2025-03-28
Active, closed
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
NCT06882746Colorectal Carcinoma, Gastric Carcinoma, Pancreatic Ductal Adenocarcinoma
Boehringer Ingelheim
Phase 1
135
California, Connecticut, Georgia, New Jersey
2025-03-28
Recruiting
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475Type 2 Diabetes
Eli Lilly and Company
Phase 2
200
Arizona, California, Florida, Georgia, Idaho, Indiana, New Jersey, New York
2025-03-28
Recruiting
MagDI U.S. Registry
NCT06928545Anastomosis, Surgical, Internal Hernia, Bowel Obstruction
GT Metabolic Solutions, Inc.
Observational
106
California, Florida, Kentucky, Louisiana, North Carolina, Washington
2025-03-28
Active, closed
Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults
NCT06869187Bipolar Disorder Depression
Autobahn Therapeutics, Inc.
Phase 2
35
California, Connecticut, Florida, Illinois, Massachusetts, New Jersey, New York, Washington
2025-03-28
Recruiting
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
NCT06854653CTCL
Prescient Therapeutics, Ltd.
Phase 2
115
California, Connecticut, Massachusetts, New York, Virginia
2025-03-28
Active, closed
Evaluation of D-Fi for the Treatment of Wounds Due to DEB
NCT06892639Dystrophic Epidermolysis Bullosa
Castle Creek Biosciences, LLC.
Phase 3
32
California, Colorado, Massachusetts
2025-03-27
Active, closed
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
NCT06920901Asthma
Apogee Therapeutics, Inc.
Phase 1
31
California, Illinois, Missouri, Oklahoma, Pennsylvania
2025-03-27
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112Endometrial Cancer
AstraZeneca
Phase 3
600
Arizona, Arkansas, California, Florida, Georgia, Hawaii, Illinois, Louisiana
2025-03-27
Recruiting
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
NCT06655246Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor, Malignant
Kura Oncology, Inc.
Phase 1
157
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Iowa
2025-03-27
Active, closed
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
NCT06818812Solid Tumors
Incyte Corporation
Phase 1
30
California, Colorado, District of Columbia, Florida, Maryland, New Jersey, Pennsylvania, Tennessee
2025-03-27
Recruiting
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
NCT06795022Hepatocellular Carcinoma
AstraZeneca
Phase 1/2
304
California, Maryland, Massachusetts, Missouri, New Jersey, Texas
2025-03-27
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company
Phase 3
700
Alabama, Arizona, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia
2025-03-27
Recruiting
The Pivotal Study of RapidPulseTM Aspiration System
NCT06029491Acute Ischemic Stroke
RapidPulse, Inc
Not applicable
170
California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Missouri
2025-03-27
Recruiting
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781Esophageal Squamous Cell Carcinoma
Daiichi Sankyo
Phase 3
510
Arizona, California, Michigan, Minnesota, Missouri, New Jersey, New York, Pennsylvania
2025-03-27
Recruiting
A Pivotal Study to Evaluate the Effectiveness of Isometric Handgrip Therapy in Elevated Blood Pressure and Hypertensive Subjects
NCT06843577Elevated Blood Pressure, Hypertension
Zona Health, Inc
Not applicable
160
California, Florida, Illinois, Kentucky, Pennsylvania, Tennessee, Texas
2025-03-27
Recruiting
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
NCT06581328Ulcerative Colitis, Crohn's Disease
Takeda
Phase 4
200
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2025-03-27
Active, closed
Siegel™ Transcatheter Aortic Valve Replacement System (TAVR) Early Feasibility Study
NCT06680427Aortic Stenosis Symptomatic
MiRus
Not applicable
30
California, Florida, Georgia, Minnesota, New Jersey, New York, Ohio
2025-03-26
Active, closed
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
NCT06857955Hypertension
Novartis Pharmaceuticals
Phase 2
396
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-03-26
Recruiting
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
NCT06932263Asthma
AstraZeneca
Phase 2
540
California, Delaware, Florida, Idaho, Indiana, Iowa, Kansas, Kentucky
2025-03-26
Recruiting
Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
NCT06827262Chronic Low-back Pain, Vertebrogenic Pain Syndrome
Boston Scientific Corporation
Observational
1,500
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Idaho, Illinois
2025-03-26
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
NCT06878261Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca
Phase 3
990
Alabama, Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois
2025-03-25
Active, closed
A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection
NCT06907290Chronic Hepatitis D Infection
Mirum Pharmaceuticals, Inc.
Phase 2/3
150
California, Florida, Illinois, Iowa, Maryland, Massachusetts, New York, Pennsylvania
2025-03-25
Recruiting
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NCT07029399HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
NiKang Therapeutics, Inc.
Phase 1
361
California, Colorado, Connecticut, Florida, Iowa, Massachusetts, Michigan, Missouri
2025-03-25
Recruiting
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
NCT06880549Advanced Solid Tumors
ModernaTX, Inc.
Phase 1
42
California, Michigan, Texas, Utah
2025-03-25
Recruiting
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
NCT06827613Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer
Marengo Therapeutics, Inc.
Phase 1/2
50
California, Massachusetts, Ohio, Tennessee, Texas
2025-03-24
Recruiting
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
NCT06810544Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor
Tango Therapeutics, Inc.
Phase 1/2
191
Arizona, California, District of Columbia, Florida, Illinois, Massachusetts, Minnesota, New York
2025-03-24
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata
NCT06826196Alopecia Areata (AA)
Aldena Therapeutics
Phase 1/2
24
California, Indiana, Massachusetts, Washington
2025-03-24
Recruiting
A Study to Assess Deucravacitinib Safety in Pregnancy
NCT07017699Psoriasis (PsO)
Bristol-Myers Squibb
Observational
900
California
2025-03-21
Active, closed
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
NCT06611163Moderate to Severe Genital Psoriasis
Sun Pharmaceutical Industries Limited
Phase 3
206
California, Colorado, Florida, Georgia, Indiana, Michigan, Nebraska, New York
2025-03-21
Recruiting
Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis
NCT06911424Bacterial Conjunctivitis
Baxis Pharmaceuticals, Inc.
Phase 3
400
Arkansas, California, Florida, Georgia, Idaho, Illinois, Maryland, Nevada
2025-03-21
Recruiting
A Comparison of NeuroSpan Bridge, NeuraGen Nerve Guide, and Nerve Autograft for Peripheral Nerve Repair
NCT06529835Peripheral Nerve Injuries
Auxilium Biotechnologies
Not applicable
80
California, Maryland, New York, Ohio, Pennsylvania, Texas
2025-03-21
Recruiting
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
NCT06914128MTAP-deleted Solid Tumors
Bayer
Phase 1/2
450
Alabama, California, Colorado, Florida, Massachusetts, Michigan, New York, Tennessee
2025-03-21
Active, closed
A Study of Navenibart in Participants With Hereditary Angioedema
NCT06842823Hereditary Angioedema (HAE)
Astria Therapeutics, Inc.
Phase 3
157
Alabama, Arizona, Arkansas, California, Colorado, Florida, Maryland, Massachusetts
2025-03-20
Active, closed
A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease
NCT06773962Parkinson's Disease (PD)
TrueBinding, Inc.
Phase 2
62
California, Colorado, Florida, Illinois, Indiana, Kansas, Michigan, New York
2025-03-20
Recruiting
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
NCT06797635Breast Neoplasms, Breast Cancer
Merck Sharp & Dohme LLC
Phase 2
372
California, Illinois, Montana, Oregon, Tennessee, Texas, Virginia
2025-03-20
Recruiting
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
NCT06874335Solid Tumor
Biohaven Therapeutics Ltd.
Phase 1
140
California, Colorado, Florida, Michigan, North Carolina, Ohio, South Carolina, Tennessee
2025-03-20
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06840392Hidradenitis Suppurativa
Novartis Pharmaceuticals
Phase 3
565
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts
2025-03-20
Recruiting
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
NCT06788912Lung Neoplasm Malignant
Merck Sharp & Dohme LLC
Phase 2
60
Alabama, California, Colorado, Maryland, Oregon, Texas, Virginia
2025-03-20
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007Ovarian Cancer
Daiichi Sankyo
Phase 3
582
California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland, Massachusetts
2025-03-19
Recruiting
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
NCT06857942Psoriasis, Overweight or Obesity
Eli Lilly and Company
Phase 4
200
Arizona, California, Florida, Georgia, Indiana, Kentucky, Maryland, Massachusetts
2025-03-19
Recruiting
TTVR STRONG Under Coverage With Evidence Development (CED) Study
NCT06833476Tricuspid Regurgitation
Edwards Lifesciences
Observational
2,044
California
2025-03-19
Recruiting
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT07032662Chronic Inflammatory Demyelinating Polyneuropathy
Immunovant Sciences GmbH
Phase 2
162
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas
2025-03-18
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
NCT06883305Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca
Phase 3
990
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-03-18
Active, closed
A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)
NCT06673056Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T)
IntraBio Inc
Phase 3
60
California, Massachusetts, Texas
2025-03-18
By invitation
An Open-Label Study of Azetukalner in Major Depressive Disorder
NCT06922110Major Depressive Disorder
Xenon Pharmaceuticals Inc.
Phase 3
460
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland
2025-03-18
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878Moderately to Severely Active Crohns Disease
Hoffmann-La Roche
Phase 3
600
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2025-03-17
Recruiting
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
NCT06805305Glioblastoma (GBM)
Diakonos Oncology Corporation
Phase 2
180
Arizona, California, Florida, Massachusetts, New Jersey, New York, North Carolina, Ohio
2025-03-17
Recruiting
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06356571Plasma Cell Myeloma Refractory
Sanofi
Phase 2
64
Arizona, California, Connecticut, District of Columbia, Florida, Louisiana, Massachusetts, Michigan
2025-03-17
Active, closed
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858878Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Amgen
Phase 3
1,105
Alabama, Arizona, California, Connecticut, Florida, Illinois, Indiana, Iowa
2025-03-17
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,000
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Idaho
2025-03-16
Recruiting
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
NCT06493552Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma
Vasgene Therapeutics, Inc
Phase 2/3
700
California
2025-03-15
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060Heart Failure
AstraZeneca
Phase 3
11,300
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2025-03-14
Active, closed
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT06795048Neovascular Age-related Macular Degeneration (nAMD)
Hoffmann-La Roche
Phase 4
274
California, Florida, Illinois, Massachusetts, Nevada, New Jersey, New Mexico, Tennessee
2025-03-14
Active, closed
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485Metastatic Castration-resistant Prostate Cancer
Celgene
Phase 3
960
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2025-03-13
Active, closed
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
NCT06869785Relapsing Multiple Sclerosis (RMS)
Novartis Pharmaceuticals
Phase 3
196
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Indiana
2025-03-13
Recruiting
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
NCT06869551Juvenile Psoriatic Arthritis
Bristol-Myers Squibb
Phase 3
60
California, Illinois, Indiana, New York, Ohio, Texas
2025-03-13
Recruiting
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
NCT06950034Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2
Solu Therapeutics, Inc
Phase 1
105
California, Florida, Massachusetts, Minnesota, Oregon, Tennessee, Texas
2025-03-13
Recruiting
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
NCT06792695Metastatic Colorectal Cancer
AstraZeneca
Phase 2
80
Arizona, California, District of Columbia, Illinois, Maryland, Massachusetts, Minnesota, New Jersey
2025-03-12
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Alabama, California, District of Columbia, Florida, Georgia, Louisiana, Massachusetts, Minnesota
2025-03-12
Active, closed
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858839Obesity
Amgen
Phase 3
3,853
Alabama, Arizona, California, Connecticut, Florida, Georgia, Hawaii, Idaho
2025-03-12
Active, closed
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
NCT06903338Viral Hepatitis
Vir Biotechnology, Inc.
Phase 3
124
Arizona, California, Florida, Illinois, Maryland, New Jersey, New York, Utah
2025-03-12
Recruiting
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
NCT06915246Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
VIVUS LLC
Phase 2
49
Arizona, California, Georgia, Illinois
2025-03-12
Active, closed
Safety and Efficacy of VDPHL01 in Males With AGA
NCT06972264Androgenetic Alopecia, AGA, Male Pattern Baldness
Veradermics, Inc.
Phase 3
480
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas
2025-03-11
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466Menstrual Migraine
Pfizer
Phase 3
723
Arizona, California, Florida, Georgia, Idaho, Indiana, Michigan, Missouri
2025-03-11
Active, closed
Response to an Investigational Device in Patients With Restless Legs Syndrome
NCT06866132Restless Legs Syndrome
Noctrix Health, Inc.
Not applicable
20
California
2025-03-11
Recruiting
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
Merck Sharp & Dohme LLC
Phase 2
308
California, Colorado, Florida, Illinois, Louisiana, Missouri, Nebraska, New York
2025-03-11
Active, closed
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
NCT06846515Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
Arthrosi Therapeutics
Phase 3
750
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Hawaii
2025-03-11
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496Psoriatic Arthritis
Takeda
Phase 3
600
Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan
2025-03-10
Recruiting
A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
NCT06789445Primary Photoreceptor Disease, Retinitis Pigmentosa (RP), Usher Syndrome, Inherited Retinal Disease (IRD)
BlueRock Therapeutics
Phase 1/2
54
California, Florida, Pennsylvania, Texas, Wisconsin
2025-03-10
Active, closed
A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine
NCT06899802Encephalitis
Bavarian Nordic
Phase 2
411
California, Georgia, Kansas, Kentucky, Louisiana, Missouri, Nebraska, Texas
2025-03-10
Recruiting
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
NCT06925542SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis
CRISPR Therapeutics
Phase 1
80
California, Illinois, Iowa, Louisiana, Massachusetts, Missouri, North Carolina, Oregon
2025-03-10
Active, closed
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
NCT06736418Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung
Abdera Therapeutics Inc.
Phase 1
17
California, Florida, Maryland, Massachusetts, Minnesota, New York, Texas, Utah
2025-03-10
Recruiting
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
NCT06528301Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), Lymphoma, Large B-Cell, Diffuse (DLBCL), Chronic Lymphocytic Leukemia (CLL)
Umoja Biopharma
Phase 1
106
California, Illinois, Missouri, Nebraska, Ohio, Washington
2025-03-10
Recruiting
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06879041Metastatic Castration-Resistant Prostate Cancer
AstraZeneca
Phase 1
136
California, Florida, Illinois, Louisiana, Massachusetts, Minnesota, Nebraska, New York
2025-03-10
Active, closed
A Study of SPY003-207 in Healthy Volunteers
NCT06873724Healthy
Spyre Therapeutics, Inc.
Phase 1
59
California
2025-03-10
Recruiting
Alleviant ALLAY-HFrEF Study
NCT06812533Heart Failure
Alleviant Medical, Inc.
Not applicable
350
California, Florida, Georgia, Illinois, Louisiana, Massachusetts, Minnesota, Missouri
2025-03-10
Active, closed
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT06744647Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
Alexion Pharmaceuticals, Inc.
Phase 2
47
Alabama, Arizona, California, Florida, Georgia, Kansas, Michigan, New Jersey
2025-03-07
Rows per page Showing 1801–1900 of 5299
Previous 17 18 19 20 21 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-usa/state/california?page=19

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,115 studies in total at the last sync on 24 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,299 of those studies with a site in California.

How many clinical trials are recruiting in California?

2,762 of the 5,299 studies on this page are recruiting new participants as of the 24 Sep 2026, 03:16 UTC sync. A further 162 have not yet opened recruitment, 2,207 are active but closed to new participants, and 168 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.